Description: Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Home Page: www.valbiotis.com
rue Paul Vatine
Périgny,
17180
France
Phone:
33 5 46 28 62 58
Officers
| Name | Title |
|---|---|
| Mr. Sébastien Peltier HDR, Ph.D. | Co-Founder, Chairman of the Management Board & CEO |
| Mr. Sebastien Bessy | COO & Member of the Management Board |
| Mr. Pascal Sirvent Ph.D. | CSO & Member of the Management Board |
| Ms. Murielle Cazaubiel | CMO & Member of the Management Board |
| Mr. Fedrick Pelong | CFO & Director |
| Dr. Josep Infesta | Head of Global Bus. Devel. |
| Mr. Philippe Sibour | Chief Exec. Officer of Alliance Consulting |
Exchange: PA
Country: FR : France
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.3811 |
| Price-to-Sales TTM: | 54.0583 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5000 |